The landscape of drug sensitivity and resistance in sarcoma

By sjmartinez • September 22, 2024

Al Shihabi A, Tebon PJ, Nguyen HTL, Chantharasamee J, Sartini S, Davarifar A, Jensen AY, Diaz-Infante M, Cox H, Gonzalez AE, Norris S, Sperry J, Nakashima J, Tavanaie N, Winata H, Fitz-Gibbon ST, Yamaguchi TN, Jeong JH, Dry S, Singh AS, Chmielowski B, Crompton JG, Kalbasi AK, Eilber FC, Hornicek F, Bernthal NM, Nelson SD, Boutros PC, Federman NC, Yanagawa J, Soragni A. The landscape of drug sensitivity and resistance in sarcoma. Cell Stem Cell. 2024 Sep 17:S1934-5909(24)00296-0. doi: 10.1016/j.stem.2024.08.010. Epub ahead of print. PMID: 39305899.

Tags: Hematology/Oncology, high-throughput drug screening, Organoids, patient-derived models, Precision medicine, Publications, sarcoma, tumor organoids

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

O'Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, Hammel P, Cremolini C, Manji GA, Oberstein PE, Garrido-Laguna I, Springfeld C, Azad[...]

Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer

Wu YL, Hochmair M, Yang Y, Yang XN, Tsuboi M, Paz-Ares L, Yang JC, Wu L, Kim HR, Rieke DT, Johnson M, Besse B, Sharma[...]

A Phase Ib Study of Efmarodocokin Alfa, an Interleukin-22 Agonist, in Combination with Standard of Care, in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Arslan S, Cutler C, Alousi A, Hamadani M, Abhyankar SH, Pusic I, Ross M, Schiller G, Dash A, Liu W, Yu Y, Lekkerkerker A, Wong[...]